Predicting the Need for Azathioprine at First Presentation in Children with Inflammatory Bowel Disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 47, Issue 2, 2008, Pages 123-129

  Mossop, Hilary ^a   Davies, P ^a   Murphy, M S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Azathioprine; Crohn disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MESALAZINE; PREDNISOLONE; STEROID; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; COLITIS; COMPARATIVE STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; PEDIATRIC WARD; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; ENTERITIS; FACTORIAL ANALYSIS; FEMALE; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; TREATMENT OUTCOME;

AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; KAPLAN-MEIERS ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56049092341     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318156a834     Document Type: Article

References (36)

1. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001;15:1699-708.
2. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
3. Singleton JW, Law DH, Kelley ML, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastro-enterology 1979;77 (4 Pt 2):870-82.
4. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
5. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercap-topurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
6. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev (3):1997:CD000067.
7. Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastro-enterol 1997;25:330-3.
8. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9.
9. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 (Suppl 1):i16-35.
10. Lloyd-Still JD. Azathioprine and the treatment of chronic inflammatory bowel disease. J Pediatr 1990;117:732-5.
11. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117:809- 14.
12. Markowitz J, Grancher K, Mandel F, et al. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pedia-tric IBD Collaborative Research Forum. Am J Gastroenterol 1993;88:44-8.
13. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
14. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41.
15. Markowitz J, Grancher K, Kohn N, et al. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol 2002;97:928-32.
16. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring, and clinical recommendations. Dig Liver Dis 2005; 37:282-97.
17. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
18. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
19. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
20. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-9.
21. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248-53.
22. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
23. De Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol 2004;4:9.
24. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60: 505-12.
25. Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000;119:1203-8.
26. Rubin K, Schirduan V, Gendreau P, et al. Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attentionto the role of puberty.J Pediatr 1993;123:863-70.
27. Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003;15:1267-73.
28. Sentongo TA, Semeao EJ, Piccoli DA, et al. Growth, body composition, and nutritional status in children and adolescents with Crohn's disease. J Pediatr Gastroenterol Nutr 2000;31:33-40.
29. Spray C, Debelle GD, Murphy MS. Current diagnosis, management, and morbidity in paediatric inflammatory bowel disease. Acta Paediatr 2000;90:400-5.
30. Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16:373-80.
31. Seidman EG. 6-mercaptopurine in maintaining remission in Crohn's disease: an old friend becomes a new hero. Gastroenterology 2000;119:1158-60.
32. Gomes P, du BC, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-5.
33. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 1994;35:231-5.
34. Holmquist L, Ahren C, Fallstrom SP. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. A study of children and adolescents with chronic inflammatory bowel disease. Acta Paediatr Scand 1990;79:527-34.
35. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990;98:811-8.
36. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterology 1992;102:1647-53.